



Federal Retail Pharmacy Program Updates

Federal Retail Pharmacy Partnership for COVID-19 website

Find up to date information and newsletters on our [website](#) for the Federal Retail Pharmacy Partnership for COVID-19.

[Sitio web en Español](#) para participantes del programa de vacunas COVID

Important updates for both programs

Reminder: Quarterly attestations were due October 14

Both the vaccine and therapeutics quarterly attestations were sent to the primary contact listed in the applicable program and were due on October 14. Pharmacies who have not returned their signed attestations risk being placed on hold and not being able to order vaccines and/or therapeutics. If you have not received your attestation(s), please email COVIDvaccines@AmerisourceBergen.com and include your pharmacy's NCPDP number and the email address you would like the attestation sent to.

Ordering: Keep your confirmation email

After placing an order, please ensure you receive the order confirmation email. Keep the confirmation for reference until you receive your order. If you believe your order has been delayed, please include your order confirmation information when contacting the COVIDvaccines@AmerisourceBergen.com mailbox.

Vaccine program updates

FDA Announces Approval for Pediatric Bivalent Boosters

On October 13, the U.S. Food and Drug Administration amended the emergency use authorizations (EUAs) of the Moderna COVID-19 Vaccine, Bivalent and the Pfizer-BioNTech COVID-19 Vaccine, Bivalent to authorize their use as a single booster dose in younger age groups.

- The Moderna COVID-19 Vaccine, Bivalent is authorized for use as single booster dose in individuals 6 years of age and older.
- The Pfizer-BioNTech COVID-19 Vaccine, Bivalent is authorized for use as a single booster dose in individuals 5 years of age and older.

The full FDA release is available at:

<https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-moderna-and-pfizer-biontech-bivalent-covid-19-vaccines>

Pediatric Booster Availability

Moderna

Moderna pediatric bivalent boosters are approved using a half-dose of the bivalent vaccine currently being administered to adults. The letter to healthcare providers with important prescribing information is available at [Moderna DHCP Letter Bivalent 10122022 \(fda.gov\)](#).

Because this vaccine is currently being administered to adults, inventory already exists in the field for use with children. Administration to pediatric patients can begin immediately using existing Moderna inventory. Please review the DHCP link above to avoid administration errors in children.

Moderna Bivalent COVID-19 Vaccine Label (adult and pediatric)



Pfizer

Pre-orders of Pfizer pediatric bivalent vaccines are expected to begin delivery on Monday, October 17. Providers may begin scheduling appointments immediately in anticipation of these deliveries.

Ordering for pediatric bivalent vaccines is open and a **top-off of your thresholds for Pfizer orange cap bivalent vaccine is expected on October 20.**

Pfizer Pediatric COVID-19 Labels (monovalent and bivalent)



Peds Bivalent Booster Orders – Specifying Adult or Pediatric Intent When Ordering

- Orders of **Moderna bivalent COVID-19 vaccines** for children aged 6-11 years will be sent with two ancillary kits per minimum dose order to accommodate double the number of doses provided in each vial.
 - **Providers will need to specify adult or pediatric intent** in their vaccine order to receive the appropriate ancillary kit.
 - Providers may opt-out of receiving ancillary kits for Moderna bivalent COVID-19 vaccines, but they must still specify pediatric intent.
 - There is no way to request a single pediatric ancillary kit. However, some sites handle this by not opting out for the first order and opting out for the second.
- **Pfizer-BioNTech bivalent COVID-19 vaccines** for children aged 5-11 years require diluent, so awardees will not be able to opt-out of receiving ancillary kits nor are they required to order with intent.
 - Ancillary kit opt-out continues to be available for all non-diluent kits

Monovalent Boosters No Longer Authorized

Monovalent mRNA COVID-19 vaccines are no longer authorized as booster doses for individuals 5 years of age and older. You are up to date with your COVID 19 vaccines if you have completed a COVID-19 vaccine primary series and received the most recent booster dose recommended for you by CDC. Anyone over the age of 5 are currently recommended to receive a bivalent booster.

Website Updates for Pediatric Bivalent Boosters

The Interim Clinical Considerations and FAQs for the pediatric bivalent boosters have been updated.

- ICCs: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html>
- FAQs: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/faq.html>

Peds Bivalent Booster Training

Pfizer Medical offers virtual training for providers of Pfizer-BioNTech COVID-19 vaccine primary series and bivalent Pfizer-BioNTech COVID-19 boosters for people 5 years of age and older. To access dates and links for upcoming training sessions, [visit the Pfizer website](#).

Moderna is providing daily opportunities for Q&A through October 28, 2022. You may register to attend any of these session at the following link: [Moderna Office Hours](#).

Mini-Webinars Regarding Bivalent COVID-19 Boosters

CDC is offering a series of brief (15-20 minute) webinars addressing topics around COVID-19 vaccination. These interactive, web-based training modules offer a real-world perspective on different issues around COVID-19 vaccines. Topics range from routine clinical and vaccine safety information to guidance for on-site clinic vaccination activities and having conversations with vaccine recipients. Each webinar includes self-test practice questions and lists additional resources related to the topic discussed.

The October 19 webinar will focus on the bivalent booster recommendations for children ages 5-11 in lieu of a COCA call. It will be pre-recorded and posted on October 19 at: [COVID-19 Vaccine Webinar Series | CDC](#).

COVID-19 Bivalent Vaccine Inventory and Wastage Guidance

When reporting wastage for bivalent boosters in children, always report wastage in full doses based on the volume identified on the label. Never report wastage in half doses. The table below is provided to assist with wastage reporting. Additional information on the identification, disposal and reporting of wastage can be found at [Identification, Disposal, and Reporting of COVID-19 Vaccine Wastage | CDC](#)

Product Label	Authorized For	Approved Administration	Dose Per Volume	Doses Per Vial	Max Reportable Inventory (Unopened Vials Only)	Max Reportable Wastage
Bivalent Vaccines						
Pfizer-BioNtech COVID-19 Vaccine Bivalent Booster	12 years and older	Booster	30mcg per 0.3mL	6	6	6
Pfizer-BioNtech COVID-19 Vaccine Bivalent Booster	5-11 y/o	Booster	10mcg per 0.2 mL	10	10	10
Moderna COVID-19 Bivalent Booster	12 years and older	Booster	50mcg per 0.5 mL	5	5	5
	6 – 11 y/o	Booster	25mcg per 0.25 mL	10	5	5

Dispose of shipping containers when there is no return label

With the fall booster campaign, a greater proportion of Moderna shipments will be using medium frozen shipping containers. As a result, effective 9/7/22 providers will receive UPS return labels for medium frozen shipping containers, in addition to the small frozen shipping containers, so that these containers may be returned and refurbished.

Please continue to dispose of any large frozen shipping containers and packing materials as you would any other waste. Providers are encouraged to recycle the cardboard components of their large frozen shipping containers through their local

recycling program.

Vaccine expiry checking

- [Pfizer-BioNTech COVID-19 Vaccine Expiry](#)
 - Pfizer Orange cap (ages 5-11) is shipping Nov 30 expiry; note bivalent coming...keep it lean
 - Pfizer Purple cap is now expired! Zero out inventory, report waste, move to Gray
- [Moderna Vial Expiration Date Look Up Tool](#)
- [Janssen COVID-19 Vaccines Expiry Checker](#)
 - Most Janssen COVID-19 vaccine in the field is now expired!
 - Limited inventory remains for ordering (all dated Jan 2023 expiry)
- [Novavax Expiry Date Checker](#)
- [CDC's COVID-19 Vaccine Lot Number and Expiration Date Report](#)

Access to this report is strictly managed by registration only. Available to public health, healthcare, and pharmacy organizations for vaccine administration, inventory, and reporting purposes.

Novavax ordering

Novavax should still be ordered by emailing the request with your NCPDP number to the COVID email box at COVIDVaccines@AmerisourceBergen.com.

- [Updated Clinical Considerations](#)

Oral therapeutics program updates

The Administration for Strategic Preparedness and Response (ASPR) and the Food and Drug Administration (FDA) announced the authorization of an extension to the shelf life from 12 months to 18 months for certain lots of the Pfizer antiviral therapy, Paxlovid (nirmatrelvir tablets and ritonavir tablets co-packaged for oral use), which is currently authorized for emergency use for the treatment of mild-to-moderate COVID-19 in certain adults and pediatric patients (12 years of age and older weighing at least 40kg).

[Table 1: Extended Expiry Dating for Paxlovid Authorized under EUA 105](#)

Please contact COVID19Therapeutics@hhs.gov with any questions and visit the [ASPR website](#) for additional information regarding Paxlovid.

Resources

Updated Implementation and Allocation Guides

- [Therapeutics Allocation guide](#)
- [Therapeutics implementation guide](#)
- [Vaccine implementation guide](#)
- [Vaccine allocation guide](#)

COVID-19 Treatment Marketing Materials

Let your patients know that you have the latest booster shot available at your pharmacy with new print and digital marketing materials. Visit the “COVID-19 Vaccine” library in [Brand Central Station](#) and [SOCi](#) to access the materials.

Surveys, reporting, reminders

Are you interested in dispensing COVID-19 antiviral therapies?

If you are currently enrolled in the vaccine program and are interested in participating in the antiviral program, please email the Elevate Enrollments team at elevateenrollments@amerisourcebergen.com.

At this time, only pharmacies enrolled in the vaccine program may participate in the antiviral program.

Questions? Continue to work with your Business Coach or Sales Executive or send questions to COVIDVaccines@AmerisourceBergen.com. Please include your pharmacy name and NCPDP on all communications. This information will help us expedite our response to you.

AmerisourceBergen

